From Novartis, Bristol MS meds to new ADCs, here are 2020’s blockbuster drug launches

From Novartis, Bristol MS meds to new ADCs, here are 2020’s blockbuster drug launches

Publication date: Feb 12, 2020

Every year, new drugs enter the market, but only a select few come bearing blockbuster potential.

According to the Drugs to Watch in 2020 list compiled by Cortellis, these 11 would-be blockbusters span several therapeutic areas, including central nervous system (CNS), oncology, hematology, inflammatory diseases and metabolic disorders.

The Novartis drug’s subcutaneous dosing could set it apart from Ocrevus’ intravenous infusion route.

Between Bristol and Novartis, each has a second drug on the list.

Outside of the BMS and Novartis MS candidates, the third CNS drug on Cortellis’ blockbuster potential list is Biohaven Pharmaceutical’s oral CGRP antagonist rimegepant for migraine.

RELATED: AZ, Daiichi’s new cancer drug Enhertu gets off to the races with quick U. S. launch Cancer therapies also occupy three spots on this year’s roster.

After a manufacturing-related complete response letter in early 2019, Immunomedics has refiled the drug for triple-negative breast cancer after two prior therapies.

While the injectable form of the drug, Ozempic, is already delivering blockbuster global sales, Rybelsus is widely viewed as a disrupter of the Type 2 diabetes landscape thanks to its oral status.

Remaining drugs on the list include Akebia Therapeutics, Mitsubishi Tanabe and Otsuka’s HIF-PH inhibitor anemia drug vadadustat, which competes against FibroGen, Astellas and AstraZeneca’s Evrenzo (roxadustat); Gilead’s rheumatoid arthritis contender filgotinib, which belongs to the same JAK inhibitor class as Pfizer’s Xeljanz, Eli Lilly’s Olumiant and AbbVie’s Rinvoq; and BioMarin’s hemophilia A gene therapy valrox that’s aiming to poach Roche drug Hemlibra’s market share.

Concepts Keywords
ADCs
Anemia
Antagonist
Antibodies
Antibody
Arena
Asset
Astellas
AZ
Blockbuster Drug
Breast
Bristol
Bristol Myers
CD19
CD20
Cel
Celgene
Central Nervous System
CEO
CGRP
CHF
Cholesterol
Cross
Daiichi Sankyo
Danish
Diabetes
FDA
Generalized Anxiety Disorder
Gilenya
Glutamate
Hematology
Hemophilia
HER2
HER2 Positive
Holy Grail
Inflammatory Diseases
Inhibitor
Intravenous Infusion
Lung
Lymphoma
Market Share
Merck
Metabolic Disorders
Migraine
Mitsubishi
Multiple Sclerosis
Novartis
Oncology
Pipeline
Receptor
Reliant
Rheumatoid Arthritis
Stomach
Subcutaneous
Swiss
Triple Negative
Tumor
Watchers

Semantics

Type Source Name
drug DRUGBANK Dimethyl fumarate
disease MESH multiple sclerosis
drug DRUGBANK Ozanimod
drug DRUGBANK Ofatumumab
drug DRUGBANK Tropicamide
disease MESH cancer
disease MESH anxiety disorder
drug DRUGBANK Spinosad
disease MESH migraine
drug DRUGBANK Rimegepant
disease MESH lymphoma
drug DRUGBANK Cholesterol
drug DRUGBANK Calcitonin gene-related peptide
disease MESH hemophilia A
pathway KEGG Rheumatoid arthritis
disease MESH rheumatoid arthritis
drug DRUGBANK Roxadustat
drug DRUGBANK Vadadustat
disease MESH anemia
disease MESH Type 2 diabetes
disease MESH breast cancer
pathway KEGG Breast cancer
disease MESH lung cancers
drug DRUGBANK Sacituzumab govitecan
disease MESH triple-negative breast cancer

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *